Healthcare / Drug Manufacturers - Specialty & GenericBSE
$28.58
+0.51 (+1.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-40.1M · quality 27.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$373M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-19.4%
↓Gross Margin
35.1%
↓Debt/Equity
1.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-36.1%
FCF CAGR
—
FCF margin
-4.3%
FCF / Net income
0.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $925.4M · net income $-124.1M · FCF $-40.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $925.4M | $925.4M | $1.46B | $2.20B | $3.54B |
| Net Income | $-124.1M | $-124.1M | $-101.4M | $-2.6M | $403.2M |
| EBITDA | $-636000.00 | $-636000.00 | $79.8M | $231.7M | $676.6M |
| EPS | -9.51 | -9.51 | -7.77 | -0.20 | 38.89 |
| Gross Margin | 35.1% | 35.1% | 34.5% | 31.1% | 35.3% |
| Operating Margin | -7.0% | -7.0% | 1.9% | 3.1% | 18.0% |
| Net Margin | -13.4% | -13.4% | -6.9% | -0.1% | 11.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.30 | 1.30 | 0.95 | 0.82 | 0.92 |
| Cash Flow | |||||
| Free Cash Flow | $-40.1M | $-40.1M | $-150.6M | $159.3M | $-166.3M |
| Returns | |||||
| ROE | -19.4% | -19.4% | -13.3% | -0.3% | 48.1% |
| Valuation | |||||
| P/E | — | — | — | — | 6.23 |
| EV/EBITDA | — | — | 18.50 | 7.54 | 4.84 |
| P/B | 0.58 | 0.58 | 0.98 | 1.21 | 3.00 |
| Growth & Yield | |||||
| Revenue Growth | -36.6% | -36.6% | -33.6% | -37.9% | — |
| EPS Growth | -22.4% | -22.4% | -3768.4% | -100.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.77 → -9.51
Residual
-1.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.